Literature DB >> 25288219

Prolonged Acetaminophen-Protein Adduct Elimination During Renal Failure, Lack of Adduct Removal by Hemodiafiltration, and Urinary Adduct Concentrations After Acetaminophen Overdose.

Steven C Curry1, Angela Padilla-Jones, Ayrn D O'Connor, Anne-Michelle Ruha, Dale S Bikin, Diana G Wilkins, Douglas E Rollins, Matthew H Slawson, Richard D Gerkin.   

Abstract

Elevated concentrations of serum acetaminophen-protein adducts, measured as protein-derived acetaminophen-cysteine (APAP-CYS), have been used to support a diagnosis of APAP-induced liver injury when histories and APAP levels are unhelpful. Adducts have been reported to undergo first-order elimination, with a terminal half-life of about 1.6 days. We wondered whether renal failure would affect APAP-CYS elimination half-life and whether continuous venovenous hemodiafiltration (CVVHDF), commonly used in liver failure patients, would remove adducts to lower their serum concentrations. Terminal elimination half-lives of serum APAP-CYS were compared between subjects with and without renal failure in a prospective cohort study of 168 adults who had ingested excessive doses of APAP. APAP-CYS concentrations were measured in plasma ultrafiltrate during CVVHDF at times of elevated serum adduct concentrations. Paired samples of urine and serum APAP-CYS concentrations were examined to help understand the potential importance of urinary elimination of serum adducts. APAP-CYS elimination half-life was longer in 15 renal failure subjects than in 28 subjects with normal renal function (41.3 ± 2.2 h versus 26.8 ± 1.1 h [mean ± SEM], respectively, p < 0.001). CVVHDF failed to remove detectable amounts of APAP-CYS in any of the nine subjects studied. Sixty-eight percent of 557 urine samples from 168 subjects contained no detectable APAP-CYS, despite levels in serum up to 16.99 μM. Terminal elimination half-life of serum APAP-CYS was prolonged in patients with renal failure for reasons unrelated to renal urinary adduct elimination, and consideration of prolonged elimination needs to be considered if attempting back-extrapolation of adduct concentrations. CVVHDF did not remove detectable APAP-CYS, suggesting approximate APAP-protein adduct molecular weights ≥ 50,000 Da. The presence of urinary APAP-CYS in the minority of instances was most compatible with renal adduct production and protein shedding into urine rather than elimination of serum adducts.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25288219      PMCID: PMC4469721          DOI: 10.1007/s13181-014-0431-2

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  22 in total

1.  Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure.

Authors:  Niraj Khandelwal; Laura P James; Corron Sanders; Anne M Larson; William M Lee
Journal:  Hepatology       Date:  2011-01-10       Impact factor: 17.425

2.  HepaRG cells: a human model to study mechanisms of acetaminophen hepatotoxicity.

Authors:  Mitchell R McGill; Hui-Min Yan; Anup Ramachandran; Gordon J Murray; Douglas E Rollins; Hartmut Jaeschke
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

3.  Expression of glutathione-dependent enzymes and cytochrome P450s in freshly isolated and primary cultures of proximal tubular cells from human kidney.

Authors:  B S Cummings; J M Lasker; L H Lash
Journal:  J Pharmacol Exp Ther       Date:  2000-05       Impact factor: 4.030

4.  Acute kidney injury in patients admitted to a liver intensive therapy unit with paracetamol-induced hepatotoxicity.

Authors:  Aisling O'Riordan; Zoe Brummell; Elizabeth Sizer; Georg Auzinger; Nigel Heaton; John G O'Grady; William Bernal; Bruce M Hendry; Julia A Wendon
Journal:  Nephrol Dial Transplant       Date:  2011-06-06       Impact factor: 5.992

Review 5.  Selective protein covalent binding and target organ toxicity.

Authors:  S D Cohen; N R Pumford; E A Khairallah; K Boekelheide; L R Pohl; H R Amouzadeh; J A Hinson
Journal:  Toxicol Appl Pharmacol       Date:  1997-03       Impact factor: 4.219

6.  Renal injury at first presentation as a predictor for poor outcome in severe paracetamol poisoning referred to a liver transplant unit.

Authors:  N Pakravan; K J Simpson; W S Waring; C M Bates; D N Bateman
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

7.  Acetaminophen-associated hepatic injury: evaluation of acetaminophen protein adducts in children and adolescents with acetaminophen overdose.

Authors:  L P James; E V Capparelli; P M Simpson; L Letzig; D Roberts; J A Hinson; G L Kearns; J L Blumer; J E Sullivan
Journal:  Clin Pharmacol Ther       Date:  2008-10-15       Impact factor: 6.875

8.  Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure.

Authors:  Laura P James; Lynda Letzig; Pippa M Simpson; Edmund Capparelli; Dean W Roberts; Jack A Hinson; Timothy J Davern; William M Lee
Journal:  Drug Metab Dispos       Date:  2009-05-13       Impact factor: 3.922

9.  Molecular basis for several drug-induced nephropathies.

Authors:  J R Mitchell; R J McMurtry; C N Statham; S D Nelson
Journal:  Am J Med       Date:  1977-04       Impact factor: 4.965

10.  Acetaminophen-cysteine adducts during therapeutic dosing and following overdose.

Authors:  Kennon J Heard; Jody L Green; Laura P James; Bryan S Judge; Liza Zolot; Sean Rhyee; Richard C Dart
Journal:  BMC Gastroenterol       Date:  2011-03-14       Impact factor: 3.067

View more
  5 in total

1.  Protein-Derived Acetaminophen-Cysteine Can Be Detected After Repeated Supratherapeutic Ingestion of Acetaminophen in the Absence of Hepatotoxicity.

Authors:  G F O'Malley; F Mizrahi; P Giraldo; R N O'Malley; D Rollins; D Wilkins
Journal:  J Med Toxicol       Date:  2015-09

2.  The Relationship Between Circulating Acetaminophen-Protein Adduct Concentrations and Alanine Aminotransferase Activities in Patients With and Without Acetaminophen Overdose and Toxicity.

Authors:  Steven C Curry; Angela Padilla-Jones; Anne-Michelle Ruha; Ayrn D O'Connor; A Min Kang; Diana G Wilkins; Hartmut Jaeschke; Kelly Wilhelms; Richard D Gerkin
Journal:  J Med Toxicol       Date:  2019-04-12

3.  Population Pharmacokinetic Modeling of Acetaminophen Protein Adducts in Adults and Children.

Authors:  Sibo Jiang; Kumpal Madrasi; Tanay Samant; Chakradhar Lagishetty; Valvanera Vozmediano; Angela Chiew; Susan M Abdel-Rahman; Laura P James; Stephan Schmidt
Journal:  J Clin Pharmacol       Date:  2019-12-04       Impact factor: 2.860

Review 4.  Extrahepatic toxicity of acetaminophen: critical evaluation of the evidence and proposed mechanisms.

Authors:  Stefanie Kennon-McGill; Mitchell R McGill
Journal:  J Clin Transl Res       Date:  2017-11-18

5.  Short-Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis.

Authors:  Mitchell R McGill; Laura P James; Sandra S McCullough; Jeffery H Moran; Samuel E Mathews; Eric C Peterson; Davis P Fleming; Morgan E Tripod; Joel H Vazquez; Stefanie Kennon-McGill; Horace J Spencer; Jonathan A Dranoff
Journal:  Hepatol Commun       Date:  2021-08-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.